Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Orthostatic hypotension]

U Schmitz1, Y Ko, S Seewald

  • 1Medizinische Universitäts-Poliklinik, Bonn.

Praxis
|March 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, *10, *11, *14 and *17 polymorphism in squamous cell cancer of head and neck.

Carcinogenesis·2001
Same author

The plasminogen activator inhibitor 1 4G/5G polymorphism is not associated with longevity: a study in octogenarians.

Journal of molecular medicine (Berlin, Germany)·2001
Same author

[An uncommon cause of severe soft tissue bleeding during phenprocoumon treatment].

Deutsche medizinische Wochenschrift (1946)·2001
Same author

Clinical differences between benign and malignant pheochromocytomas.

Endocrine journal·2001
Same author

Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2001
Same author

[Chronic progressive polycythemia and thrombocytosis].

Praxis·2001
Same journal

Praxis·2026
Same journal

[What do Swiss doctors think about cardiovascular risk factors and guidelines?]

Praxis·2026
Same journal

[Laser interstitial thermotherapy (LITT): a minimally invasive neurosurgical treatment option for brain tumours and radiation necrosis].

Praxis·2026
Same journal

[Persistent back pain after lifting trauma. From the trivial to the rare case].

Praxis·2026
Same journal

[A patient with dizziness and gait instability - a diagnostic challenge].

Praxis·2026
Same journal

[Meningoencephalitis caused by listeria monocytogenes].

Praxis·2026
See all related articles

Shy-Drager syndrome, a rare neurological disorder, can cause severe orthostatic hypotension. Continuous norepinephrine infusion effectively improved symptoms in a 67-year-old patient, offering a new treatment avenue.

Area of Science:

  • Neurology
  • Autonomic Dysfunction
  • Pharmacology

Background:

  • Shy-Drager syndrome (SDS) is a rare, sporadic, neurodegenerative disorder characterized by autonomic failure.
  • Patients often present with symptoms including orthostatic hypotension, urinary incontinence, and Parkinsonism.
  • Diagnosis typically involves tests assessing sympathetic nervous system response, such as the Schellong test.

Observation:

  • A 67-year-old woman exhibited progressive orthostatic vertigo, urinary incontinence, and Parkinson's disease signs.
  • The Schellong test indicated a deficient sympathetic orthostatic pressure response with no plasma norepinephrine increase.
  • This clinical presentation led to the diagnosis of Shy-Drager syndrome.

Findings:

  • Standard treatments for orthostatic hypotension, including compressive pantyhose, sympathomimetic agonists, and alpha-2-antagonists, proved ineffective.

Related Experiment Videos

  • Continuous administration of norepinephrine via a miniature dosing pump was initiated.
  • This therapeutic approach resulted in a significant improvement in the patient's orthostatic hypotension.

    • Implications:

    • Continuous norepinephrine infusion represents a viable and effective treatment strategy for refractory orthostatic hypotension in Shy-Drager syndrome.
    • This case highlights the importance of considering advanced therapeutic options when conventional treatments fail.
    • Further research into optimized drug delivery systems for autonomic failure disorders is warranted.